LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to measure the depigmenting effect of a serum product called Liftactiv B3 in patients with mild to moderate facial PIHP (Post Inflammatory Hyper Pigmentation)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Collaborator: Vichy Laboratoires
• Treatments: Sunscreening Agents

Criteria

Inclusion Criteria:

• Multiethnic subjects

• 18 to 50 YO

• Phototype III-VI

• All skin types

• 50% with sensitive skin (declarative)

• Symmetrical mild to moderate facial post-acne PIHP lesions with IGA scale

• Mild active acne (less than 10 retention and 5 inflammatory lesions)

• Agreeing not to change their lifestyle during the study period.

• Capable of reading the documents presented to them, of adhering to the study regulations and accepting the limitations.

• Available to follow the study

• Agreeing to participate and having signed the informed consent

Exclusion Criteria:

• Moderate to severe active acne

• Patients under topical or systemic retinoids

• Patients under systemic immunosuppressants

• Patients under active treatment of PIHP (including topicals or procedures) within the last 3 months

• Patients treated with facial procedures within the last 3 months

• Pregnancy

• Patient with a recent change in contraception (since less than 6 months)

• Known allergy to any component of tested product

• Not presenting with the conditions needed to comply with the protocol.

• Unable to give their informed consent

• Not available to follow the study in its entirety